Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPL-003 intranasal dose-finding study in treatment-resistant depression with open-label extension
2024-513457-70-00Phase 2Completed
- Sponsor
- Beckley Psytech
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of mebufotenin in treatment-resistant depression (TRD) and major depressive disorder (MDD) (3 arms), sponsored by Beckley Psytech. Primary endpoints: Change from baseline in MADRS between BPL-003 dose groups, Treatment-emergent adverse events in open-label extension and 4 more. Started Sep 2024; status: completed.
02
Drugs
mebufotenin
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-513457-70-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513457-70-00.